Title |
Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation
|
---|---|
Published in |
Cancer Imaging, April 2018
|
DOI | 10.1186/s40644-018-0146-8 |
Pubmed ID | |
Authors |
Babina Gosangi, Matthew Davids, Bhanusupriya Somarouthu, Francesco Alessandrino, Angela Giardino, Nikhil Ramaiya, Katherine Krajewski |
Abstract |
The last 5 years have been marked by profound innovation in the targeted treatment of chronic lymphocytic leukemia (CLL) and indolent lymphomas. Using CLL as a case study, we present a timeline and overview of the current treatment landscape for the radiologist, including an overview of clinical and radiological features of CLL, discussion of the targeted agents themselves, and the role of imaging in response and toxicity assessment. The goal is to familiarize the radiologist with multiple Food and Drug Administration (FDA)-approved targeted agents used in this setting and associated adverse events which are commonly observed in this patient population. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 50% |
Science communicators (journalists, bloggers, editors) | 1 | 50% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 40 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 6 | 15% |
Other | 4 | 10% |
Student > Ph. D. Student | 4 | 10% |
Researcher | 4 | 10% |
Student > Master | 4 | 10% |
Other | 6 | 15% |
Unknown | 12 | 30% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 14 | 35% |
Pharmacology, Toxicology and Pharmaceutical Science | 6 | 15% |
Biochemistry, Genetics and Molecular Biology | 2 | 5% |
Nursing and Health Professions | 1 | 3% |
Chemical Engineering | 1 | 3% |
Other | 2 | 5% |
Unknown | 14 | 35% |